PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31332769-10	2019	Recently, there has been a resurgence of its use due to the US Food and Drug Administration approval of an extended-release (ER) amantadine formulation for treatment of L-dopa-induced dyskinesia.	Levodopa	169-175	epiregulin	Homo sapiens	125-127	
6953463-4	1982	After levodopa treatment, only patients with left symptomatology responded to the attention task with an enlargement of EP components, largely in the noninvolved hemisphere.	Levodopa	6-14	epiregulin	Homo sapiens	120-122	
28236251-4	2017	A new extended-release (ER) carbidopa-levodopa capsule product (also referred to as IPX066) was developed and approved in the US as Rytary  and in the EU as Numient .	Levodopa	38-46	epiregulin	Homo sapiens	24-26	
28236251-6	2017	Phase III studies of this ER carbidopa-levodopa capsule formulation in patients with PD have shown a significant reduction in "off" time compared with IR carbidopa-levodopa and carbidopa-levodopa-entacapone.	Levodopa	39-47	epiregulin	Homo sapiens	26-28	
28236251-7	2017	We present a review of the clinical pharmacokinetics and pharmacodynamics of this ER product of carbidopa-levodopa in healthy subjects and in patients with PD.	Levodopa	106-114	epiregulin	Homo sapiens	82-84	
26692288-2	2016	Carbidopa/levodopa ER capsules contain beads of carbidopa and levodopa, designed to release the drugs at different rates in the gastrointestinal tract and provide constant therapeutic levodopa concentrations that are maintained for 4-5 h (after an initial peak at   1 h).	Levodopa	10-18	epiregulin	Homo sapiens	19-21	
26692288-2	2016	Carbidopa/levodopa ER capsules contain beads of carbidopa and levodopa, designed to release the drugs at different rates in the gastrointestinal tract and provide constant therapeutic levodopa concentrations that are maintained for 4-5 h (after an initial peak at   1 h).	Levodopa	62-70	epiregulin	Homo sapiens	19-21	
26692288-3	2016	In randomized phase III trials, oral carbidopa/levodopa ER was significantly more effective than placebo with regard to improving motor symptoms and activities of daily living in patients with early PD after 30 weeks" treatment, and provided significantly greater reductions in daily "off-time" in patients with advanced PD than immediate-release (IR) carbidopa/levodopa or carbidopa/levodopa IR plus entacapone after a treatment period of 13 and 2 weeks, respectively, without increasing troublesome dyskinesia.	Levodopa	47-55	epiregulin	Homo sapiens	56-58